These conditions, such as post-menopausal vasomotor symptoms (PMVMS), are debilitating for women and associated with significant healthcare and economic costs.
KaNDy Therapeutics was spun out from NeRRe Therapeutics in 2017, and at the same time, all formulation, pre-clinical and clinical safety and efficacy data, and intellectual property associated with NT-814 was transferred to KaNDy Therapeutics.
NT-814 has successfully completed a Phase 2a proof of concept study demonstrating its potential to reduce both the frequency and severity of hot flashes, and is now being prepared to enter an international Phase 2b study in this anchor indication. It has the potential to be a unique first-in-class treatment for this debilitating disorder, representing a non-hormonal alternative to hormone replacement therapy.
Post-menopausal vasomotor symptoms affect up to 75% of peri-menopausal women. Symptoms last for 1–2 years after menopause in most women, but may continue for up to 10 years or longer in others. Approximately 20% of women will have debilitating symptoms on a daily basis.
Hot flashes are the primary reason women seek medical care at menopause. Hot flashes not only disturb women at work and interrupt daily activities, but also have a detrimental effect on sleep. Post-menopausal symptoms are experienced daily by millions of women globally.
KaNDy Therapeutics is led by an experienced management team and backed by internationally recognised life sciences investors: Advent Life Sciences, Fountain Healthcare Partners, Forbion Capital Partners and OrbiMed.
KaNDy Therapeutics is based at the state-of-the-art Stevenage Bioscience Catalyst, the UK’s first open innovation bioscience campus.